Associated tags: Invitrogen, Thermo Fisher Scientific, Health, Patheon, Applied Biosystems, Science, Fisher Scientific, Laboratory, Research, PPD, TMO, NYSE, Other Science, Mindful Scientific Inc., Biotechnology, Pharmaceutical, Medical Devices
Locations: EUROPE, ASIA PACIFIC, ASIA, USA, AMERICAS, UNITED STATES, NORTH AMERICA, MASSACHUSETTS, SWEDEN
Science,
Other Science,
Research,
BNY Mellon,
ADS,
American depositary receipt,
Thermo Fisher Scientific,
TMO,
Bank,
DNB ASA,
Sales management,
Letter The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink.
Key Points:
- The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink.
- The Offer is now scheduled to expire at 5:00 p.m., New York time, on June 18, 2024, unless the Offer is extended or earlier terminated.
- These Shares and ADSs collectively represent approximately 94.3% of the outstanding Shares as of such time.
- Olink shareholders who have already tendered their Shares or ADSs of Olink do not have to re-tender their Shares or ADSs or take any other action as a result of the extension of the expiration time of the Offer.
Retrieved on:
Wednesday, April 24, 2024
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2024 Investor Day on Thursday, September 19, starting at 9:00 a.m. (ET) in New York City.
Key Points:
- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2024 Investor Day on Thursday, September 19, starting at 9:00 a.m. (ET) in New York City.
- The format will feature presentations by members of Thermo Fisher Scientific’s senior management team and conclude with a Q&A session.
- The live webcast of the presentation can be accessed via the Investors section of our website, www.thermofisher.com .
- A replay of the webcast will be available following the presentation.
Retrieved on:
Wednesday, April 24, 2024
Oncology,
Health,
Research,
Pharmaceutical,
Science,
Biotechnology,
Table,
GAAP,
Safety,
Water,
Pustular psoriasis,
Ion chromatography,
Disease,
Thermo Fisher Scientific,
Patient,
EPS,
GMP,
TMO,
Video game Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024.
Key Points:
- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024.
- “We are very pleased to deliver another quarter of strong financial results,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific.
- GAAP operating income for the first quarter of 2024 grew to $1.66 billion, compared with $1.56 billion in the year-ago quarter.
- Adjusted operating income for the first quarter of 2024 was $2.28 billion, compared with $2.33 billion in the year-ago quarter.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2024 before the market opens on Wednesday, April 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.
Key Points:
- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2024 before the market opens on Wednesday, April 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.
- During the call, the company will discuss its financial performance, as well as future expectations.
- To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S.
- You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com .
Science,
Other Science,
Research,
ADS,
TMO,
Bank,
Sales management,
Letter,
Thermo Fisher Scientific,
American depositary receipt,
DNB ASA,
BNY Mellon The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink.
Key Points:
- The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink.
- The Offer is now scheduled to expire at 5:00 p.m., New York time, on April 30, 2024, unless the Offer is extended or earlier terminated.
- These Shares and ADSs collectively represent approximately 95.2% of the outstanding Shares as of such time.
- Olink shareholders who have already tendered their Shares or ADSs of Olink do not have to re-tender their Shares or ADSs or take any other action as a result of the extension of the expiration time of the Offer.
Retrieved on:
Wednesday, February 28, 2024
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the TD Cowen Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. (EST).
Key Points:
- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the TD Cowen Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. (EST).
- You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .
Retrieved on:
Wednesday, February 21, 2024
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on April 15, 2024, to shareholders of record as of March 15, 2024.
Key Points:
- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on April 15, 2024, to shareholders of record as of March 15, 2024.
- This reflects an 11% increase over the previous dividend payment of $0.35.
Retrieved on:
Wednesday, January 31, 2024
Oncology,
Health,
Research,
Pharmaceutical,
Science,
Biotechnology,
Multiple myeloma,
EPS,
COVID-19,
Table,
CSR,
GAAP,
STEM,
Risk assessment,
Thermo Fisher Scientific,
Binding site,
S/TEM,
TMO,
FDA,
Laboratory,
COVID-19 testing,
Proteomics,
Pre-eclampsia,
Health equity,
Electricity,
Video game Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023.
Key Points:
- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023.
- GAAP operating income for the fourth quarter of 2023 was $1.85 billion, compared with $1.86 billion in the year-ago quarter.
- Adjusted EPS in the fourth quarter of 2023 was $5.67, versus $5.40 in the fourth quarter of 2022.
- Adjusted operating income for the fourth quarter of 2023 was $2.55 billion, compared with $2.56 billion in the year-ago quarter.
Retrieved on:
Thursday, January 4, 2024
Science,
Other Science,
Research,
ADS,
Thermo Fisher Scientific,
Sales management,
Bank,
TMO,
DNB ASA,
Letter,
BNY Mellon,
American depositary receipt,
Security (finance) The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink.
Key Points:
- The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink.
- The Offer is now scheduled to expire at 5:00 p.m., New York time, on February 29, 2024, unless the Offer is extended or earlier terminated.
- These Shares and ADSs collectively represent approximately 94.1% of the outstanding Shares as of such time.
- Olink shareholders who have already tendered their Shares or ADSs of Olink do not have to re-tender their Shares or ADSs or take any other action as a result of the extension of the expiration time of the Offer.
Retrieved on:
Wednesday, January 3, 2024
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. (EST).
Key Points:
- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. (EST).
- You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .
